9-Fluor-11β,17-dihydroxy-16β-methylpregna-1,4-dien-3,20-dion-21-[tricyclo[3.3.1.13,7]dec-1-ylformiat]

9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-[tricyclo[3.3.1.13,7]dec-1-ylformate] Struktur
40242-27-1
CAS-Nr.
40242-27-1
Bezeichnung:
9-Fluor-11β,17-dihydroxy-16β-methylpregna-1,4-dien-3,20-dion-21-[tricyclo[3.3.1.13,7]dec-1-ylformiat]
Englisch Name:
9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-[tricyclo[3.3.1.13,7]dec-1-ylformate]
Synonyma:
9-Fluoro-11β,17-dihydroxy-16β-methyl-21-[tricyclo[3.3.1.13,7]decan-1-ylcarbonyloxy]pregna-1,4-diene-3,20-dione;9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-[tricyclo[3.3.1.13,7]dec-1-ylformate]
CBNumber:
CB5930429
Summenformel:
C33H43FO6
Molgewicht:
554.695
MOL-Datei:
40242-27-1.mol

9-Fluor-11β,17-dihydroxy-16β-methylpregna-1,4-dien-3,20-dion-21-[tricyclo[3.3.1.13,7]dec-1-ylformiat] Eigenschaften

Sicherheit

9-Fluor-11β,17-dihydroxy-16β-methylpregna-1,4-dien-3,20-dion-21-[tricyclo[3.3.1.13,7]dec-1-ylformiat] Chemische Eigenschaften,Einsatz,Produktion Methoden

Originator

Betamethasone,Zhejiang Xianju Pharmaceutical Co., Ltd.

Therapeutic Function

Glucocorticoid

9-Fluor-11β,17-dihydroxy-16β-methylpregna-1,4-dien-3,20-dion-21-[tricyclo[3.3.1.13,7]dec-1-ylformiat] Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


9-Fluor-11β,17-dihydroxy-16β-methylpregna-1,4-dien-3,20-dion-21-[tricyclo[3.3.1.13,7]dec-1-ylformiat] Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 0)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate

40242-27-1(9-Fluor-11β,17-dihydroxy-16β-methylpregna-1,4-dien-3,20-dion-21-[tricyclo[3.3.1.13,7]dec-1-ylformiat])Verwandte Suche:


  • 9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-[tricyclo[3.3.1.13,7]dec-1-ylformate]
  • 9-Fluoro-11β,17-dihydroxy-16β-methyl-21-[tricyclo[3.3.1.13,7]decan-1-ylcarbonyloxy]pregna-1,4-diene-3,20-dione
  • 40242-27-1
Copyright 2019 © ChemicalBook. All rights reserved